CA2573565A1 - Method of diagnosing, monitoring and treating pulmonary diseases - Google Patents

Method of diagnosing, monitoring and treating pulmonary diseases Download PDF

Info

Publication number
CA2573565A1
CA2573565A1 CA002573565A CA2573565A CA2573565A1 CA 2573565 A1 CA2573565 A1 CA 2573565A1 CA 002573565 A CA002573565 A CA 002573565A CA 2573565 A CA2573565 A CA 2573565A CA 2573565 A1 CA2573565 A1 CA 2573565A1
Authority
CA
Canada
Prior art keywords
group
atp
lung function
difference
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002573565A
Other languages
English (en)
French (fr)
Inventor
Amir Pelleg
Peter J. Barnes
Sergei A. Kharitonov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duska Scientific Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2573565A1 publication Critical patent/CA2573565A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
CA002573565A 2004-07-22 2005-07-22 Method of diagnosing, monitoring and treating pulmonary diseases Abandoned CA2573565A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US59010104P 2004-07-22 2004-07-22
US60/590,101 2004-07-22
US66203305P 2005-03-15 2005-03-15
US60/662,033 2005-03-15
PCT/US2005/026884 WO2006012639A2 (en) 2004-07-22 2005-07-22 Method of diagnosing, monitoring and treating pulmonary diseases

Publications (1)

Publication Number Publication Date
CA2573565A1 true CA2573565A1 (en) 2006-02-02

Family

ID=35786780

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002573565A Abandoned CA2573565A1 (en) 2004-07-22 2005-07-22 Method of diagnosing, monitoring and treating pulmonary diseases

Country Status (6)

Country Link
US (2) US20060029548A1 (cg-RX-API-DMAC10.html)
EP (1) EP1773405A4 (cg-RX-API-DMAC10.html)
JP (1) JP2008507368A (cg-RX-API-DMAC10.html)
AU (1) AU2005266887B2 (cg-RX-API-DMAC10.html)
CA (1) CA2573565A1 (cg-RX-API-DMAC10.html)
WO (1) WO2006012639A2 (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1924264T1 (sl) * 2005-09-01 2013-12-31 F. Hoffmann-La Roche Ag Diaminopirimidini kot modulatorji p2x3 in p2x2/3
US8157837B2 (en) 2006-03-13 2012-04-17 Pneumrx, Inc. Minimally invasive lung volume reduction device and method
US9402633B2 (en) 2006-03-13 2016-08-02 Pneumrx, Inc. Torque alleviating intra-airway lung volume reduction compressive implant structures
US8888800B2 (en) 2006-03-13 2014-11-18 Pneumrx, Inc. Lung volume reduction devices, methods, and systems
US8632605B2 (en) 2008-09-12 2014-01-21 Pneumrx, Inc. Elongated lung volume reduction devices, methods, and systems
SG173647A1 (en) 2009-02-13 2011-10-28 Shionogi & Co Novel triazine derivative and pharmaceutical composition containing same
US20100222294A1 (en) * 2009-02-27 2010-09-02 Duska Scientific Co. Formulations of ATP and Analogs of ATP
JP5809621B2 (ja) 2009-05-18 2015-11-11 ヌームアールエックス・インコーポレーテッド 患者の肺を治療するインプラント
WO2011159974A2 (en) * 2010-06-17 2011-12-22 The Johns Hopkins University TARGETING THE ALPHA3 SUBUNIT OF Na+K+-ATPase FOR THE TREATMENT OF COUGH WITH SULFENAMIDES
US9718790B2 (en) 2010-08-10 2017-08-01 Shionogi & Co., Ltd. Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same
JP6138044B2 (ja) * 2011-08-10 2017-05-31 国立大学法人富山大学 痺れ又は自発痛の評価方法及び薬物のスクリーニング方法
JP6124351B2 (ja) 2012-02-09 2017-05-10 塩野義製薬株式会社 複素環および炭素環誘導体
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
PE20160431A1 (es) 2013-08-23 2016-06-02 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica
WO2015061790A2 (en) 2013-10-25 2015-04-30 Pneumrx, Inc. Genetically-associated chronic obstructive pulmonary disease treatment
US10390838B1 (en) 2014-08-20 2019-08-27 Pneumrx, Inc. Tuned strength chronic obstructive pulmonary disease treatment
US11272864B2 (en) 2015-09-14 2022-03-15 Health Care Originals, Inc. Respiratory disease monitoring wearable apparatus
US11622716B2 (en) 2017-02-13 2023-04-11 Health Care Originals, Inc. Wearable physiological monitoring systems and methods
CA2998742C (en) 2015-09-29 2023-08-29 Anthony P. FORD Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
WO2017184993A1 (en) * 2016-04-22 2017-10-26 The Regents Of The University Of California Monitoring and modulation of parasympathetic nervous system
US10955269B2 (en) 2016-05-20 2021-03-23 Health Care Originals, Inc. Wearable apparatus
US20210278418A1 (en) * 2018-03-15 2021-09-09 The Chidlren's Medical Center Corporation Method for treating asthma or allergic disease
CN113164488A (zh) 2018-10-05 2021-07-23 盐野义制药株式会社 慢性咳嗽治疗用药物
CN117843615A (zh) 2019-09-19 2024-04-09 盐野义制药株式会社 1,3,5-三嗪衍生物或其溶剂合物的晶体及其制造方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122466A (en) * 1989-06-13 1992-06-16 North Carolina State University Ballistic transformation of conifers
JP3121827B2 (ja) * 1990-09-04 2001-01-09 メドコ・リサーチ・インコーポレイテッド アデノシンまたはそのリン酸化誘導体を活性成分とする気管支収縮性肺疾患の診断剤
GB9109063D0 (en) * 1991-04-26 1991-06-12 Ici Plc Modification of lignin synthesis in plants
US5527586A (en) * 1992-03-18 1996-06-18 Printron, Inc. Apparatus and method for depositing metal particles on a dielectric substrate
US5348616A (en) * 1993-05-03 1994-09-20 Motorola, Inc. Method for patterning a mold
FR2709666B1 (fr) * 1993-09-07 1995-10-13 Oreal Composition cosmétique ou dermatologique constituée d'une émulsion huile dans eau à base de globules huileux pourvus d'un enrobage cristal liquide lamellaire.
EP0760850A1 (en) * 1994-05-27 1997-03-12 Glaxo Group Limited P2x RECEPTORS (PURINOCEPTOR FAMILY)
US5597613A (en) * 1994-12-30 1997-01-28 Honeywell Inc. Scale-up process for replicating large area diffractive optical elements
US6482742B1 (en) * 2000-07-18 2002-11-19 Stephen Y. Chou Fluid pressure imprint lithography
US6309580B1 (en) * 1995-11-15 2001-10-30 Regents Of The University Of Minnesota Release surfaces, particularly for use in nanoimprint lithography
US5874420A (en) * 1995-12-26 1999-02-23 Allegheny University Of The Health Sciences Process for regulating vagal tone
US5850020A (en) * 1996-09-11 1998-12-15 Genesis Research & Development Corporation, Ltd. Materials and method for the modification of plant lignin content
US6653528B1 (en) * 1996-09-11 2003-11-25 Genesis Research & Development Corporation Limited Pinus radiata nucleic acids encoding O-methyl transferase and methods for the modification of plant lignin content therewith
US6204434B1 (en) * 1996-09-11 2001-03-20 Genesis Research & Development Corporation Limited Materials and methods for the modification of plant lignin content
US6410718B1 (en) * 1996-09-11 2002-06-25 Genesis Research & Development Corporation Ltd. Materials and methods for the modification of plant lignin content
US5735985A (en) * 1996-11-15 1998-04-07 Eastman Kodak Company Method for micromolding ceramic structures
CA2288821C (en) * 1997-03-25 2008-10-14 Allegheny University Of The Health Sciences Modulation of human mast cell activation
US6225143B1 (en) * 1998-06-03 2001-05-01 Lsi Logic Corporation Flip-chip integrated circuit routing to I/O devices
US6110401A (en) * 1998-08-24 2000-08-29 Physical Optics Corporation Method and apparatus for replicating light shaping surface structures on a rigid substrate
US6190929B1 (en) * 1999-07-23 2001-02-20 Micron Technology, Inc. Methods of forming semiconductor devices and methods of forming field emission displays
US6517995B1 (en) * 1999-09-14 2003-02-11 Massachusetts Institute Of Technology Fabrication of finely featured devices by liquid embossing
PT1255544E (pt) * 2000-01-31 2007-06-15 Genaera Corp Inibidores da síntese da mucina.
US6387787B1 (en) * 2001-03-02 2002-05-14 Motorola, Inc. Lithographic template and method of formation and use
EP1392643B1 (en) * 2001-05-18 2005-09-14 Abbott Laboratories Trisubstituted-n- (1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
US6716754B2 (en) * 2002-03-12 2004-04-06 Micron Technology, Inc. Methods of forming patterns and molds for semiconductor constructions

Also Published As

Publication number Publication date
EP1773405A4 (en) 2011-10-05
US20100286274A1 (en) 2010-11-11
AU2005266887A1 (en) 2006-02-02
WO2006012639A3 (en) 2006-06-22
US20060029548A1 (en) 2006-02-09
WO2006012639A2 (en) 2006-02-02
JP2008507368A (ja) 2008-03-13
EP1773405A2 (en) 2007-04-18
AU2005266887B2 (en) 2011-08-18
WO2006012639A9 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
US20100286274A1 (en) Methods of Diagnosing, Monitoring and Treating Pulmonary Diseases
Moskowitz et al. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms
Scharfman et al. N-methyl-D-aspartate receptors contribute to excitatory postsynaptic potentials of cat lateral geniculate neurons recorded in thalamic slices.
Boushey et al. Bronchial hyperreactivity
Cerrina et al. Comparison of human bronchial muscle responses to histamine in vivo with histamine and isoproterenol agonists in vitro
Garthwaite et al. Synaptic activation of N-methyl-D-aspartate and non-N-methyl-D-aspartate receptors in the mossy fibre pathway in adult and immature rat cerebellar slices
Whicker et al. Responsiveness of bronchial smooth muscle from asthmatic patients to relaxant and contractile agonists
Basoglu et al. Effects of aerosolized adenosine 5′-triphosphate in smokers and patients with COPD
Fryer et al. Dysfunction of M2-muscarinic receptors in pulmonary parasympathetic nerves after antigen challenge
Fox et al. An in vitro study of the properties of single vagal afferents innervating guinea‐pig airways.
Vidruk et al. Mechanisms by which histamine stimulates rapidly adapting receptors in dog lungs
Taylor et al. Airway reactivity in chronic obstructive pulmonary disease: failure of in vivo methacholine responsiveness to correlate with cholinergic, adrenergic, or nonadrenergic responses in vitro
Dick et al. Correlation of recruitment order with axonal conduction velocity for supraspinally driven diaphragmatic motor units
Smith et al. Organization of gustatory sensitivities in hamster superior laryngeal nerve fibers
Benson et al. Bronchial reactivity: interaction between vagal stimulation and inhaled histamine
Oh et al. Reflex regulation of airway sympathetic nerves in guinea‐pigs
Nikolaev et al. Single mechanically-gated cation channel currents can trigger action potentials in neocortical and hippocampal pyramidal neurons
Verduyn et al. The effect of flunarizine and ryanodine on acquired torsades de pointes arrhythmias in the intact canine heart
Tung et al. Peripheral induction of burst firing in locus coeruleus neurons by nicotine mediated via excitatory amino acids
Borsody et al. Alteration of locus coeruleus neuronal activity by interleukin-1 and the involvement of endogenous corticotropin-releasing hormone
Lin et al. Hypersensitivity of vagal pulmonary afferents induced by tumor necrosis factor alpha in mice
Enarson et al. Predictors of bronchial hyperexcitability in grainhandlers
Chung Review Series: Chronic cough: Future directions in chronic cough: mechanisms and antitussives
Buron et al. Oxytocin modulates respiratory heart rate variability through a hypothalamus–brainstem–heart neuronal pathway
Katsuki et al. Effects of acetylcholine on hypoglossal and C4 nerve activity in brainstem-spinal cord preparations from newborn rat

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130723